Peter Boyd Sells 10,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Key Points

• Peter Boyd sold 10,000 shares of Aquestive Therapeutics at an average price of $7.00, totaling $70,000, which represents a 3.59% decrease in his ownership.
• Aquestive Therapeutics reported earnings per share of ($0.14), outperforming analysts' expectations, but missed revenue estimates with $10 million against a forecast of $11.32 million.
• Institutional investors and hedge funds now own approximately 32.45% of Aquestive Therapeutics' stock, following significant boosts in holdings by several large investors.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Peter Boyd sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total transaction of $70,000.00. Following the completion of the sale, the insider directly owned 268,323 shares in the company, valued at $1,878,261. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock traded up $0.07 on Friday, reaching $7.08. The company had a trading volume of 3,309,585 shares, compared to its average volume of 1,911,560. The firm's 50 day moving average price is $5.00 and its two-hundred day moving average price is $3.81. The firm has a market cap of $706.02 million, a PE ratio of -10.11 and a beta of 1.77. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $7.51.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after buying an additional 276,295 shares in the last quarter. Pale Fire Capital SE boosted its holdings in shares of Aquestive Therapeutics by 25.5% in the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company's stock valued at $5,549,000 after buying an additional 340,767 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Aquestive Therapeutics by 7.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company's stock valued at $3,073,000 after buying an additional 75,275 shares in the last quarter. Sio Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 141.9% in the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company's stock valued at $3,136,000 after buying an additional 555,860 shares in the last quarter. Finally, Everstar Asset Management LLC boosted its holdings in shares of Aquestive Therapeutics by 119.5% in the 2nd quarter. Everstar Asset Management LLC now owns 658,607 shares of the company's stock valued at $2,180,000 after buying an additional 358,607 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Zacks Research raised shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 13th. Lifesci Capital raised shares of Aquestive Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 3rd. JMP Securities upped their target price on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a "market outperform" rating in a research note on Thursday, October 9th. Oppenheimer upped their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday, September 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $10.71.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.